The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20260811: Kirin Holdings Company, Ltd.; Amgen Inc.
20260813: U.S. Bancorp; Condor Trading, LP
20260815: ISQ Global Infrastructure Fund IV, L.P.; Triton Fund IV L.P.
Express Scripts, Inc., et al.; Analysis of Agreement Containing Consent Order To Aid Public Comment
Adamas
The Federal Trade Commission ordered building services contractor Adamas Amenity Services LLC (Adamas) and its affiliated businesses to cease their enforcement of no-hire agreements.
Adamas used anticompetitive no-hire agreements that restrict building owners and management companies across New Jersey and New York City from directly hiring workers employed by Adamas without a significant penalty, according to the FTC’s complaint. Adamas is required to immediately cease enforcing all existing no-hire agreements under a proposed FTC order. On February 12, 2026, the FTC finalized the consent order with Adamas and its affiliated businesses.
Noncompete Rule
20260749: Hogan Lovells US LLP; Cadwalader, Wickersham & Taft LLP
20260752: Impala IGT NewCo Limited; Warburg Pincus Jovian GG, L.P.
20260758: BioMarin Pharmaceutical Inc.; Amicus Therapeutics, Inc.
20260767: Eli Lilly and Company; Ventyx Biosciences, Inc.
20260771: American Water Works Company, Inc.; IIF US Holdings 2 LP
20260775: New Mountain Partners VI, L.P.; New Mountain Partners VI Aggregator, L.P.
20260776: New Mountain Partners VI Aggregator, L.P.; New Mountain Partners VI, L.P.
20260784: Rite-Hite Holding Corporation Voting Trust; Randall L. Johnson
Golden Sunrise Nutraceutical, Inc.
In July 2020, the Federal Trade Commission filed a complaint in federal court against the California-based marketers and promoters of bogus treatments for serious medical conditions. The defendants are two corporations headquartered in Porterville, California, and two of their executives: Huu Tieu, president and CEO of both companies; and Stephen Meis, Medical Director and board member of Golden Sunrise Nutraceutical. The complaint alleged that defendants have promoted and sold a variety of products through "plans of care" ranging in price from $23,000 to $200,000, which falsely claim to treat or cure COVID-19, cancer, Parkinson's disease, etc. On June 14, 2021, the FTC announced a proposed order barring the defendants from making bogus health claims. In January 2024, the FTC announced the process defrauded consumers can use to seek refunds. In February 2026, the FTC announced it was sending refund checks to eligible consumers, as well as an online process for eligible consumers who have not yet submitted a claim to do so.